AFT licenses Pascomer(R) for Europe

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





17 March 2021

AFT licenses Pascomer
®
for Europe
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed a new
commercialisation and development agreement for its orphan drug Pascomer
®
,

covering the 27 countries within the European Union as well as Switzerland, Norway
and the United Kingdom.
The agreement, with Desitin Arzneimittel GmbH, a specialist pharmaceutical
company based in Hamburg, Germany, builds on the 2019 North American
commercialisation and development agreement for Pascomer with Timber
Pharmaceuticals Inc.
Pascomer is being developed to treat facial angiofibromas, a symptom of Tuberous
Sclerosis Complex (TSC), a genetic disease, estimated to affect one in 6,000
1
people,
or an estimated 50,000 patients across Europe
2
.
Around 66% of those with TSC over the age of two suffer from facial angiofibromas
2
,
which can cause adverse effects on appearance and in serious cases, impair
breathing and vision
2
. At present there is no standard treatment for the symptom
2
.
AFT Pharmaceutical Managing Director Dr Hartley Atkinson says: “We are delighted
to partner with Desitin, which has excellent coverage and expertise in this therapeutic
area across Europe.”
Dr Atkinson said the agreement further demonstrated AFT’s success in driving the
commercialisation of its intellectual property around the world, despite the travel
restrictions imposed by the COVID-19 pandemic.
“This is the second major agreement this year that has been entirely negotiated and
sealed remotely. Our patented medicines, Maxigesic
®
, Pascomer and our long-lasting
hand sanitiser Crystawash
®
Extend, are being enthusiastically embraced by partners
around the world.
“It is a testament to both the efficacy of these products and the commitment of the
AFT team to work through the restrictions of the pandemic to deliver these
agreements. They are not only driving improved health outcomes globally, but also
driving the realisation of the significant latent value we see in our medicine portfolio,”
Dr Atkinson said.
Released for and on behalf of AFT Pharmaceuticals by Chief Financial Officer
Malcolm Tubby.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical business with a broad range of
products, both developed itself and in-licensed from third parties. AFT’s products
cover all major pharmaceutical distribution channels: over-the-counter, prescription
and hospital. Historically, AFT’s home markets have been Australia, New Zealand and
South-East Asia. However, the company is out-licensing its own products to licensees
and distributors to sell in an increasing number of countries around the world. The
company’s intensive Research and Development program forms the basis of its
international sales strategy. For more information about the company, visit our website
www.aftpharm.com
.
About Desitin Arzneimittel GmbH
Desitin is a German pharmaceutical company who focus on the development and
sales of medication for illnesses of the central nervous system in the European
continent. Desitin specialize in sophisticated products for the treatment of
neurological and psychiatric diseases, with an expertise in skin care.
References
1
Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, et al.
Genotype/phenotype correlation in 325 individuals referred for a diagnosis of
tuberous sclerosis complex in the United States. Genet Med. 2007 Feb;9(2):88–100.

Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, et al. Mutational analysis
in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2,
compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64–80.

2
Tuberous Sclerosis Alliance: https://www.tsalliance.org/